Pharmacokinetic Effect of AstraGin on Whey Protein Absorption and Muscle Function in Healthy Subjects

NCT06110260 | Completed

• 1 other identifier: CS1-23151
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

This study gave healthy people supplements with ginseng and astragalus saponin extracts (AstraGin), combined with whey protein, to explore whether it can promote amino acid absorption and thereby enhance protein nutritional status and muscle function. This trial is a randomized, double-blind, crossover trial, and the research subjects are adult healthy subjects.

Conditions

Pharmacokinetic Effect of AstraGin on Whey Protein Absorption and Muscle Function in Healthy Subjects

Keywords

BCAA; Ginseng and Astragalus Saponin Extract; Whey Protein; Pharmacokinetics

Outcome Measures

Primary Outcomes (1)

• The AUC of BCAA in human plasma

  Pharmacokinetic ( 0, 15, 30, 45, 60, 90, 120, 150, and 180 minutes)

  3 hr

Secondary Outcomes (3)

• Plasma TAC Test

  4weeks、12weeks

• Grip Strength

  4weeks、12weeks

• Muscle Mass-DXA

  4weeks、12weeks

Study Arms (2)

AstraGin

EXPERIMENTAL

The 1st round: Before each study day, all subjects took a 50 mg AstraGin capsule at 9 p.m. and began fasting for 12 hours, except for a small amount of water the night before the experiment. On each study day, all subjects collected their first blood sample at 9 a.m. from the median cubital vein using the indwelling catheter method. After the first blood collection, all subjects took 50 mg AstraGin and 35 g of whey protein with 250 mL water. Additional blood samples were collected at 0, 15, 30, 45, 60, 90, 120, 150, and 180 min to analyze the plasma concentration of amino acids. The washout period is seven days, during which the subjects maintain a stable lifestyle and dietary habits. The 2nd round: All subjects take a 50 mg AstraGin capsule and conduct the procedure (same as the 1st round)

Dietary Supplement: AstraGin (Ginseng and Astragalus Saponin Extract)

Placebo

PLACEBO COMPARATOR

The 1st round: Before each study day, all subjects took a 50 mg placebo (maltodextrin) capsule at 9 p.m. and began fasting for 12 hours, except for a small amount of water the night before the experiment. On each study day, all subjects collected their first blood sample at 9 a.m. from the median cubital vein using the indwelling catheter method. After the first blood collection, all subjects took 50 mg placebo and 35 g of whey protein with 250 mL water. Additional blood samples were collected at 0, 15, 30, 45, 60, 90, 120, 150, and 180 min to analyze the plasma concentration of amino acids. The washout period is seven days, during which the subjects maintain a stable lifestyle and dietary habits. The 2nd round: All subjects take a 50 mg Placebo capsule and conduct the procedure (same as the 1st round)

Dietary Supplement: Placebo

Interventions

AstraGin (Ginseng and Astragalus Saponin Extract) DIETARY_SUPPLEMENT

In this study, we are investigating the effects of AstraGin on healthy adults. The testing sample is orally administrated to subjects with 35g whey protein + AstraGin. After intervention, a 180-min kinetics study of plasma amino acids was conducted.

AstraGin

Placebo DIETARY_SUPPLEMENT

In this study, we are investigating the effects of AstraGin on healthy adults. The testing sample is orally administrated to subjects with 35g whey protein + Placebo. After intervention, a 180-min kinetics study of plasma amino acids was conducted.

Placebo

Eligibility Criteria

• Age: 20 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Healthy adults and aged 20-65 years.
• Subject has provided written informed consent to participate in the study.
• The subject is willing and able to comply with the study.

You may not qualify if:

• The subject is participating in another clinical trial thirty days prior to enrollment.
• Subject allergy to milk proteins
• Subject has any medical condition or uses any medication, nutritional product, amino acids supplement, or program which might interfere with the conduct of the study or place the subject at risk.
• Subjects lost to follow-up, non-compliance, and concomitant medication.

Sponsors & Collaborators

• Chung Shan Medical University: lead

Study Sites (1)

Chung Shan Medical University

Taichung, Taiwan

Location

MeSH Terms

Interventions

Asian ginseng

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: PREVENTION
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 26, 2023
• First Posted: October 31, 2023
• Study Start: March 30, 2024
• Primary Completion: October 30, 2024
• Study Completion: October 30, 2024
• Last Updated: December 18, 2025

Record last verified: 2025-12

Locations

TW (1)